OncoPharm

This gift-giving season, we ask whether we want to Keep, Re-gift, or Return new oncology drugs approved this past year.

The FDA's pilot program, project renewal, uses capecitabine for its first label makeover. What's new & what are the possible implications of the DPYD warning now in the prescribing information?

Thought on: Double Dauno, but they said it better --> (https://open.spotify.com/episode/0eHEl3bUdZdg3mynUiNMG6?si=88cdab4b882e4667) Blinatumumab FTW The end of "the" neutropenic diet?

Tumor-Infiltrating Lymphocytes (TILs) getting closer to entering practice. Updated survival results published from DESTINY-Breast03 (T-DXd vs. T-DM1). A new IDH1 inhibitor, olutasidenib, is FDA-approved for relapsed or refractory AML.

Recent voluntary withdrawals from the US market of belantamab-mafodotin and atezolizumab's indication for bladder cancer have us weighing (again) the pros & cons of the accelerated approval program. Also, FDA approves the 1st fecal transplant product.

Discover a groundbreaking antibody-drug conjugate now approved for ovarian cancer! Dive into how mirvetuximab soravtansine targets folate receptor alpha, delivering a powerful DM4 microtubule inhibitor. Learn about practical prescribing, infusion procedures, and the management of potential eye toxicity. The podcast also highlights response rates from trials and discusses the implications of negative phase 3 results. Get insights on patient selection and where this innovative therapy fits in the treatment landscape.

We review the 5-year update of CheckMate 227 and the POSEIDON to generate the hypothesis that CLTA-4 inhibition has a role in PD-L1 negative metastatic NSCLC. CM 227 update: https://pubmed.ncbi.nlm.nih.gov/?term=36223558 POSEIDON: https://pubmed.ncbi.nlm.nih.gov/?term=36327426 Editorial: https://pubmed.ncbi.nlm.nih.gov/?term=36331243

The International Nonproprietary Names (INN) unit from WHO decided to drop the -mab suffix from new drug names. Instead, -tug, -bart, -ment, and -mig will be used. We have some thoughts. INN Report: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9122354/#

New Drug Approvals! -Tremelimumab, the 2nd CTLA-4 inhibitor, finally gets approved. -Teclistamab, an excited BCMA-CD3 T-cell engager for multiple myeloma.

The discussion revolves around pemetrexed as a maintenance treatment for non-small cell lung cancer. It breaks down the differences between switch and continuation maintenance strategies, highlighting pivotal studies that shaped current approaches. Patient demographics and treatment side effects are also examined, providing valuable insights into the effectiveness and challenges of this therapy.